#United States #Veeva Systems #San Francisco #Clinical Trials #MedTech Industry

Veeva MedTech: A Leap Forward in Clinical Trials

In an exciting development for the medtech industry, Veeva Systems (NYSE: VEEV) has announced the adoption of its clinical applications by more than 50 medtech companies, including 11 of the world’s top 20 medtech firms and seven out of the top 10 clinical research organizations (CROs). This partnership aims to simplify and accelerate the process of conducting medical device and diagnostic studies, paving the way for more comprehensive and efficient clinical trials.

The Need for Modern Solutions

As the regulatory landscape becomes increasingly complex and the demand for medical innovations grows, companies within the medtech sector are transitioning from outdated systems that often exist in silos. Instead, they are embracing Veeva’s modern and integrated applications designed to connect various aspects of clinical trial processes. This shift not only fosters greater collaboration but also adheres to essential compliance standards across local, regional, and global markets.

With the integration of Veeva’s Clinical applications, medtech companies find themselves equipped with tools that enhance scalability and help streamline clinical operations. By implementing Veeva’s Electronic Data Capture (EDC), organizations report impressive improvements: they experience up to 50% faster study setup times and eliminate up to 80% of duplicate trial documents through the Veeva eTrial Master File (eTMF).

Voices from the Industry

Veeva’s impressive impact on clinical trials is echoed by industry leaders who have embraced their platform. Kevin Liang, Vice President of Clinical Strategy at Veeva MedTech, expresses enthusiasm about collaborating with medtech industry giants to cultivate a connected infrastructure for clinical trials, which ultimately aids in expediting the delivery of life-saving medical products to patients.

Leianne Ebert, head of clinical data operations at Alcon, shares her experiences with Veeva EDC: “We’ve closely partnered with their team to enhance our global library and develop reusable standards.” Her commitment to standardization resulted in a staggering 50% improvement in compliance, demonstrating the value of organizational cohesion through Veeva’s platform.

LifeNet Health’s Vice President of Global Clinical Affairs, Kimberly Dorsch, highlights the consistency and regulatory acceptance enabled by Veeva’s systems: “Whether it's a registry study or an IDE/IND study supporting a PMA/BLA, data will be collected in a compliant manner.” This consistency is crucial for ensuring that studies meet regulatory standards and can ultimately lead to successful product approval.

Moreover, Matt Christensen, Senior Vice President of Global Clinical and Medical Affairs at Smith+Nephew, points out remarkable efficiencies achieved since implementing Veeva eTMF: “We’ve reduced our quality control time by over 90% and significantly decreased our document creation times.” Such drastic reductions allow teams to focus on delivering higher-quality insights from clinical trials.

Conclusion

As Veeva Systems continues to redefine clinical trial methodologies through its innovative technology, it is evident that a new era in the medtech industry is unfolding. The combination of faster study timelines, improved compliance, and enhanced collaboration stands to not only transform how clinical trials are conducted but also ultimately facilitate quicker patient access to groundbreaking medical technologies.

For those interested in exploring Veeva's Clinical Platform applications further, more information is available at veeva.com/MedTechClinical where comprehensive resources are provided.

About Veeva Systems

Veeva Systems is recognized as the global leader in cloud software tailored for the life sciences sector. With a commitment to product excellence and customer satisfaction, Veeva caters to a diverse clientele, encompassing some of the largest biopharmaceutical corporations as well as emerging biotech firms. As a Public Benefit Corporation, Veeva emphasizes striking a balance among the extensive interests of various stakeholders, including customers, employees, shareholders, and the broader industry.

For additional information, visit veeva.com/eu.